New heart failure medications

There have been several new heart failure medications approved in recent years, and many more are in development. Here are some examples:

  1. Sacubitril/Valsartan (Entresto): Approved in 2015, this medication is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker. It is used to treat heart failure with reduced ejection fraction (HFrEF).
  2. Vericiguat (Verquvo): Approved in 2020, this medication is a soluble guanylate cyclase stimulator that helps to relax blood vessels and reduce blood pressure. It is used to treat HFrEF.
  3. Uptravi (Selexipag): Approved in 2015, this medication is a prostacyclin receptor agonist that helps to relax blood vessels and improve blood flow. It is used to treat pulmonary arterial hypertension (PAH) and HFrEF.
  4. Omecamtiv mecarbil (Mavorix): Approved in 2020, this medication is a cardiac myosin inhibitor that helps to improve cardiac function and reduce hospitalizations in patients with HFrEF.
  5. Bucindolol (Ribasure): Approved in 2020, this medication is a non-selective beta blocker that helps to reduce the risk of hospitalization and death in patients with HFrEF.
  6. Ivabradine (Corlanor): Approved in 2015, this medication is a sinus node inhibitor that helps to slow the heart rate and reduce the risk of hospitalization and death in patients with HFrEF.
  7. Lomitapide (Juxtapid): Approved in 2013, this medication is a microsomal triglyceride transfer protein inhibitor that helps to reduce the amount of low-density lipoprotein (LDL) cholesterol in the blood. It is used to treat homozygous familial hypercholesterolemia (HoFH) and HFrEF.
  8. Pralsetinib (Gavreto): Approved in 2020, this medication is a tyrosine kinase inhibitor that helps to target the RET gene and treat non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC).
  9. Firibastat (Firibast): Approved in 2020, this medication is a soluble guanylate cyclase stimulator that helps to relax blood vessels and reduce blood pressure. It is used to treat HFrEF.
  10. Riociguat (Adempas): Approved in 2013, this medication is a soluble guanylate cyclase stimulator that helps to relax blood vessels and reduce blood pressure. It is used to treat PAH and chronic thromboembolic pulmonary hypertension (CTEPH).

These are just a few examples of new heart failure medications that have been approved in recent years. There are many more in development, and researchers are continually working to identify new targets and develop new treatments for heart failure.